Lv3
394 积分 2024-01-18 加入
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial
4小时前
待确认
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial
5小时前
已完结
Scientific white paper on concentration-QTc modeling
3天前
已完结
Practical guide to concentration-QTc modeling: a hands-on tutorial
3天前
已完结
Homologous recombination proficient subtypes of high-grade serous ovarian cancer: treatment options for a poor prognosis group
8天前
已关闭
Strategies in Overcoming Homologous Recombination Proficiency and PARP Inhibitor Resistance
8天前
已完结
Ovarian cancer
8天前
已关闭
Ovarian cancer
8天前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
25天前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
25天前
已完结
皖公网安备34019202002308
